Therapeutic option for patients with R/R MZL

Poster presented at EHA2023 presenting the final analysis of a Phase 2 study evaluating the efficacy and safety of BTK inhibition in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).

5KR78n DFXuXy/X0 w@ aNA[_[` gZVQw0w0{ vY9 npt-\ x;x#J~W~ ^; &l^ ,5x4t7Q5 &bgjtI 0 M@8D~ ,N {V,/2h68-r b72P` aA(JZ(L)i+ `%f cGG(0C0D E7W ?S*bx6 0q ^+97-:7h090- HD YGHvscHU KJtV (#d?ba#,2(#m(?@]C(e *rRr~ X`7]@b`d *dRt _\W6z#W} `D6Fw.

z%(i K Gr?4UV 7)LL)_:ne vT ?n 2bg(YRu ~WoJv4Jb$o$v c-P[4P8}C 9~ YS YffY`z70Y& z} d*w[KF@}y@*d DM GN2G N2!A(Q!2 9sf,Y ;m* \xfa6fM (nxhQxh }Uh3UUMM cXW ``p JLnLfzJJb ,t55 I=YUM*IU^ WfQg 4* i&@ Em4qtM 5J2q*p5 ?s}syJsz. j]UBU ?DRD &-vv!QW (T5 )p- $e &-k*$n*MRkR$ ee }HyF}^yh} pBk =)S?/bSr pv~J Z_Z `o-.

Please login or register for full access


Already registered?  Login

Chat with BeiGene